(Q40616812)

English

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

scientific article published on February 1, 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

1 reference

10.1038/SJ.LEU.2403205

https://api.crossref.org/works/10.1038/SJ.LEU.2403205

1 April 2024

Jacques Van Dongen

5

object named as

J. J M. van Dongen

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

author name string

I. Jedema

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

R. M Y. Barge

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

V. H J. van der Velden

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

B. A. Nijmeijer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

R. Willemze

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

J. H F. Falkenburg

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14614514

1 April 2024

publication date

1 February 2004

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

full work available at URL

https://www.nature.com/articles/2403205.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614514

1 April 2024

https://www.nature.com/articles/2403205.pdf

Portable Document Format

1 reference

10.1038/SJ.LEU.2403205

https://api.crossref.org/works/10.1038/SJ.LEU.2403205

1 April 2024

https://www.nature.com/articles/2403205

1 reference

10.1038/SJ.LEU.2403205

https://api.crossref.org/works/10.1038/SJ.LEU.2403205

1 April 2024

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

316-325

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Chemistry and biology of natural and designed enediynes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Positivity of the proliferation marker Ki-67 in noncycling cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

21 January 2018

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in CD33 intensity between various myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403205

7 January 2021

based on heuristic

inferred from DOI database lookup

29

75

252

author name string

M Danova

publication date

1990

1 reference

10.1038/SJ.LEU.2403205

https://api.crossref.org/works/10.1038/SJ.LEU.2403205

1 April 2024

Identifiers

10.1038/SJ.LEU.2403205

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40616812&oldid=2203832568"